



European
Reference
Network

for rare or low prevalence
complex diseases



Network
Neurological Diseases
(ERN-RND)



ean
european academy of neurology



European
Reference
Network

for rare or low prevalence
complex diseases



Network
Neuromuscular
Diseases (ERN EURO-NMD)



Webinar – 11.October 2022

Krabbe disease – natural history and treatment options

by Ingeborg Krägeloh-Mann*

University Hospital Tübingen, Germany



***on behalf of the 'lysosomal team'
(Samuel Gröschel, Christiane Kehrler,
Vidiyahaa Santhanakumaran,
Sarah Krieg, Lucia Laugwitz)
Ludger Schöls – Neurology
Ralf Husain – Jena
Volkmar Gieselmann - Bonn**



**European
Reference
Network**

for rare or low prevalence
complex diseases



Network
Neurological Diseases
(ERN-RND)



ean

european academy of neurology



**European
Reference
Network**

for rare or low prevalence
complex diseases



Network
Neuromuscular
Diseases (ERN EURO-NMD)



Learning objectives

- **By the end of this webinar you will be able to:**
 - **discuss the different forms and dynamics of Krabbe's disease**
 - **identify the first symptoms of the disease**
 - **know about the role of neuroimaging, biochemistry and genetics for diagnosis and counselling**
 - **understand the treatment options**



**European
Reference
Network**

for rare or low prevalence
complex diseases



Network
Neurological Diseases
(ERN-RND)



ean

european academy of neurology



**European
Reference
Network**

for rare or low prevalence
complex diseases



Network
Neuromuscular
Diseases (ERN EURO-NMD)



Webinar outline

- Introduction
- Methods
- Natural history and imaging findings
- Diagnostic procedures
- Treatment options

Two histories – what do they have in common?

Normal development during the first 4 months.

The child then gets irritable, often cries and gets into opisthotonus.

It does not grasp any more, has less visual contact

- marked irritability and tone increase


- peripheral neuropathy

Normal development into the 2nd decade.

Then gait appears a bit strange, 'staggery', clumsy (retrospectively hollow feet since 4 yrs)

- Demyelinating polyneuropathy

- Pyramidal signs



Two histories – what do they have in common?

Normal development during the first 4 months.


The child then gets irritable, often cries and gets into opisthotonus.

It does not grasp any more, has less visual contact

- marked irritability and tone increase

- peripheral neuropathy

MRI at 6 months




Normal development into the 2nd decade.

Then gait appears a bit strange, 'staggery', clumsy (retrospectively hollow feet since 4 yrs)

- Demyelinating polyneuropathy

- Pyramidal signs

MRI at 13 yrs



Morbus Krabbe

globoidcell leucodystrophy

- rare lysosomal storage disorder
- mutations in the GALC gene lead to a deficiency of the enzyme β -Galactocerebrosidase

Suzuki und Suzuki, 1970, Proceedings of the National Academy of Sciences of the United States of America

- Classical infantile form:
early and rapid progression lead to an early death

Duffner et al. 2011 Pediatric Neurology; Bascou et al. 2019 Orphanet J Rare Dis

- Other disease courses are less well known

Kolodny 1991 Dev Neurosci; Loonen et al. 2004 Neuropediatrics; Duffner et al., 2012 Pediatric Neurology, Pediatric Neurology; Debs et al 2013 J Inherit Metab Dis.; Hosain et al 2014 Gene; Bascou et al. 2018 Orphanet J Rare Dis.

Data and methods

- Collection of developmental milestones (gain and loss of motor function, language and cognition) by means of a standardized questionnaire.
- Evaluation of MRIs with
 - A standardized Krabbe score [Loes et al., 1999, *AJNR*] and
 - Classification to patterns according to Abdelhalim et al., 2014, *Pediatric Neurology*
- Clinical data of 38 patients
- MRI data: 40 MRIs of 27 patients

Onset

Frequency distribution all forms of Krabbe




Fig 1 from Krieg et al. Orphanet Journal of Rare Diseases (2020) 15:243

Onset

Frequency distribution all forms of Krabbe




Fig 1 from Krieg et al. Orphanet Journal of Rare Diseases (2020) 15:243

Symptoms at onset

symptoms which led to diagnostic identification:

Early symptoms at infantile onset (0 to 12 months)


- | | | | |
|------|---|-------|-----|
| → 1. | Agitation/Irritability | 24/30 | 80% |
| 2. | Abnormalities in movement pattern and
general development regression | 19/30 | 63% |

Early symptoms at a later onset (from 13 months on)

- | | | | |
|------|---|-----|------|
| → 1. | Gait disorder/Abnormalities in movement pattern | 8/8 | 100% |
| 2. | Abnormalities in fine motor skills | 5/8 | 63% |
| 3. | General development regression | 5/8 | 50% |

Clinical course of disease


early infantile



Early milestones achieved, but then quickly lost
Death usually before second birthday

Clinical course of disease


early infantile



Early signs: loss of fixation, need for gastric tube

MRI – pattern - early

early infantile




- **White matter**
Central region
- **Dentate nucleus and cerebellar white matter**
- **Corpus callosum**
- **Pyramidal tract**

Age at MRI 5 months, onset 2 months.


MRI-score - course

early infantile



In particular cases the score can deteriorate extremely within a few weeks. One child f.ex. showed a deterioration from 10 to 22 points within 6 weeks.

MRI – pattern - late *early infantile*




Age at MRI 8 months, onset 4 months.

- cystic degeneration of the pyramidal tract
T2w hyperintense
Flair hypointense
- global atrophy
- Extensive white matter involvement

MRI - pattern

late infantile




- White matter
Central region
- Corpus callosum
- Pyramidal tract
- Cerebellar white matter without dentate nucleus

Age at MRI 12 months onset 9 months

MRI - pattern

late infantile



Age at MRI 12 months


Age at MRI 19 months

Onset 9 months

- White matter
Central region
 - Corpus callosum
 - Pyramidal tract
 - Cerebellar white
matter without
dentate nucleus
- affected later**
- Severe white matter
changes
 - atrophy

Clinical course of disease


later onset



Individual courses of gross motor function according to the GMFC-MLD

Clinical course of disease *later onset*


32 patients,
9 onset 12 months – 3 yrs



Bascou et al. A prospective natural history study of Krabbe disease in a patient cohort with onset between 6 months and 3 years of life. Orphanet Journal of Rare Diseases 2018; 13:126


MRI - pattern

later onset



Age at MRI 5 years 1 months, onset 5 years.









- White matter parieto-occipital
- Corpus callosum (Body and Splenium)
- Pyramidal tract



→ Also a late-infantile (onset 10,5 months) and an adolescent patient (onset 12 years) show such a pattern


MRI - pattern

later onset



MRI - pattern

adolescent, adult




- Pyramidal tract

Age at MRI 70 years, onset 60 years.

MRI - pattern

later onset


Only pyramidal tract involvement



Age at MRI 4 ½ years, onset 4 years.

Summary

clinical characteristics



infantile

early 0 - 6 months
late 7 - 12 months

**irritability, spasticity and neuropathy,
visual loss (optic atrophy)
tube feeding, cognitive decline,
rapid and homogeneous decline**

later onset adolescent and adult

13 months - 10 yrs
adolescent 11 - 20 yrs
adult > 20 yrs

**primary motor signs (gait disorder) – PNS+CNS
variable course,
especially in adult onset protracted course
cognitive symptoms are later signs**


In common

**development normal before onset of first symptoms
(only exceptionally early infantile Krabbe may start
without clearly first normal development**

additional features

**neuropathy (nerve conduction velocity↓)
CSF protein ↑**

Survival according to onset



From the world-wide registry (Duffner et al, 2012)

Summary

MRI – early signs



infantile

early
late

0 - 6 months
7 - 12 months

central white matter, pyramidal tract

cerebellum: dentate nucleus, cerebellar white matter



later onset



adolescent and adult

13 months - 10 yrs

adolescent 11 - 20 yrs

adult > 20 yrs

peritrogonal white matter,
corpus callosum (splenium)
pyramidal tract



Specific diagnostic procedures

biochemistry

β -Galactocerebrosidase activity

artificial substrates are preferred due to their technical advantages, their sensitivity and specificity

But they have a risk for false positive or negative results because of the different chemical properties of artificial substrates


When there is a mismatch between clinical, genetic and biochemical findings

➡ Repeat with an assay based on radioactive labelled natural substrate

No correlation with onset of the disease

As also found by others

(f.ex. Komatsuzaki et al, 2019 Genetics in Medicine)



Santhanakumaran et al. Poster SSIEM 2022

Specific diagnostic procedures

genetics

Deletions and mutations in the GALC gene

More than 140 different pathogenic variants of the GALC gene

Little genotype-phenotype correlation

- **30 kb deletion** (c.1161 + 6532_polyA+9kdel)* - infantile onset
- **mutation c.857G>A** (p.Gly286Asp) – later onset

Prediction difficult because of

- *compound heterocytosity*
- *Other variants not clearly related to course.*

*with about 45 % of the mutated alleles by far the most common mutation in the Caucasian population (here in 4 infantile and 1 later onset patients)


Sakai N, Otomo T.. J Neurosci Res. 2016

Duffner PK, Jalal K, Carter RL Pediatr Neurol. 2009

diagnostic procedures

CSF protein

CSF higher in earlier onset
(data from 248 published cases)



Komatsuzaki et al.. Genetics in Medicine, 2019

Treatment options

stemcell transplantation

Escolar ML et al. N Engl J Med 2005;352:2069-2081.

Infantile Krabbe

11 asymptomatic newborns


(positive family history)

14 symptomatic infants

(diagnosed between four - nine months of age)


Transplantation of umbilical-cord blood from unrelated donors.

Survival – age (months)



Neurodevelopmental Outcomes

Escolar ML et al. N Engl J Med 2005;352:2069-2081.



Ten of the 11 patients in the newborn group were evaluated after transplantation.

In the symptomatic group, 8 of the 14 patients were evaluated in all domains.

None of the symptomatic patients improved appreciably in any area

Treatment options

stemcell transplantation – early infantile Krabbe

Patients: 18 presymptomatic babies

- detected by **newborn screening** or
- diagnosed prenatally or neonatally because of family history.

Inclusion criteria

- (1) diagnosis of early-infantile Krabbe disease established by family history or deficiency of GALC activity in peripheral blood leukocytes and
- (2) HSCT within 7 weeks after birth

3/18 died from complications related to HSCT


1/18 died from surgical complications (6 yrs)

1/18 died from disease progression

One of the surviving patients has normal cognitive function and 10 continue to develop cognitive skills at a slightly slower rate than normal.

Treatment options

stemcell transplantation – Krabbe late infantile and beyond



Clinical trials on Krabbe Disease

1. AAV9-gene therapy (Passage Bio)

1. Single application, intracisternal
2. > 1 months and < 9 months, presymptomatic or early symptomatic < 6 months
3. Minimum level of neurological development (head lifting, eye tracking, smiling)
4. 1 EU center (Amsterdam)
5. Only one patient yet treated in the US

2. Combination of HSCT and AAV10-gene therapy (Forge therapeutics)

1. Intravenous
2. Phase 1/ 2 clinical study of intravenous gene transfer with an AAV10 vector expressing GALC after HSCT
3. Infantile KD, 1d to 12 months of age
4. Eligible for HSCT, reasonable neurological function stabilized after HSCT
5. US only

Q1 Natural history in Krabbe Disease is characterized by

Correct are three

1. Global developmental delay as first symptoms
2. First development is usually normal
3. Motor signs such as gait disorder are first signs in onset beyond the first year of life
4. Disease course is rapid and homogeneous in the early infantile form
5. In later onset forms age at onset has clearly been shown to predict progression of the disease

Q1 Natural history in Krabbe Disease is characterized by


1. Global developmental delay as first symptoms
2. First development is usually normal
3. Motor signs such as gait disorder are first signs in onset beyond the first year of life
4. Disease course is rapid and homogeneous in the early infantile form
5. In later onset forms age at onset has clearly been shown to predict progression of the disease

Correct are 2, 3 ,4


Q2 Which MRI is characteristic for Krabbe Disease?

Correct are two


1.




3.




5.



2.



4.




6.



Q2 Which MRI is characteristic for Krabbe Disease?


Correct are 1 and 4

1.




Krabbe
Early infantile

3.



PMD

5.



X-ALD
frontal form

2.




Adult MLD
HDLS may look similar

4.



Krabbe
Later onset

6.



PVL

Q3 Specific diagnostics in Krabbe Disease relies on

Correct are three

1. Deficient β -Galactocerebrosidase activity
2. Mutations of the ARSA gene
3. Deletions and mutations in the GALC gene
4. Enzyme activity is clearly relate to onset of the disease
5. There is a high genotype-phenotype correlation
6. In unclear cases an assay using radioactive labelled natural substrate is to be preferred

Q3 Specific diagnostics in Krabbe Disease relies on

Correct are 1, 3, 6

1. Deficient β -Galactocerebrosidase activity
2. Mutations of the ARSA gene
3. Deletions and mutations in the GALC gene
4. Enzyme activity is clearly relate to onset of the disease
5. There is a high genotype-phenotype correlation
6. In unclear cases an assay using radioactive labelled natural substrate is to be preferred

Key conclusions

- Different forms of disease with different clinical courses and MRI patterns – infantile, especially early infantile, Krabbe is the most frequent form, later onset forms are different with respect to first signs, dynamics and imaging
- Diagnostic procedures
 - enzyme measurement (cave pitfalls, when using artificial substrate)
 - genotype (little phenotype correlation)
- (New) treatment options
 - stemcell transplantation (presymptomatic infantile, early symptomatic later onset)
 - gene therapy trials

NEXT Webinar

‘DBS in Dystonia – Targets, programming and therapeutic challenges’

**by Philipp Capetian,
University Hospital Würzburg, Germany**

18. October 2022

